Pfizer is an over-100-year-old drug company going through a rough patch, which has happened before.

Pfizer and major pharma names draw fresh attention as healthcare rotation, pipeline strength, and patent risks shape the ...

Why Pfizer (PFE) is on investors’ radar today Pfizer (PFE) is back in focus after recent share price moves, with the stock ...

Pfizer (NYSE:PFE) has entered a global oncology partnership with Innovent Biologics worth up to $10.5b, focused on up to 12 ...

Pfizer (NYSE: PFE) is a high-yielding stock that's trading at a low valuation. The problem is, it's been that way for some time now. The stock's lack of movement in one direction or another seems to ...

Let's keep this most recent development in perspective. While it's true that Pfizer's stock dropped by about 2.5% on the news of the former leaders throwing their lot in with the reigning management ...

Pfizer’s PFE third-quarter revenue fell 6%, as acquisition charges outweighed cost efficiencies and pushed adjusted diluted EPS down 18%. In the battle for Metsera’s obesity pipeline, Pfizer announced ...

Pfizer PFE reported stronger third-quarter results than we anticipated, largely due to significantly higher sales of covid-19 treatment Paxlovid, which also drove management to increase its top- and ...

Shares of the pharmaceutical giant trade at less than 9 times its future earnings. Investors are likely concerned about upcoming patent cliffs that may weigh down its financials. However, the company ...